Search

Your search keyword '"A. Charles Rabinowitz"' showing total 2 results
Start Over Author "A. Charles Rabinowitz"
2 results on '"A. Charles Rabinowitz"'

1. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions

Author

Dominic J. Allocco, Christophe Dubois, Gregg W. Stone, Paul S. Teirstein, Joseph Dens, Robert L. Feldman, Tommy C. Lee, Vincent J. Pompili, Shigeru Saito, Keith D. Dawkins, A. Charles Rabinowitz, Ian T Meredith, Louis Cannon, and Michael R. Mooney

Subjects
Target lesion, medicine.medical_specialty, business.industry, medicine.medical_treatment, Percutaneous coronary intervention, Stent, General Medicine, medicine.disease, Surgery, Lesion, Coronary artery disease, Cohort, Cardiovascular agent, medicine, Radiology, Nuclear Medicine and imaging, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Prospective cohort study
Abstract

Objectives To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Methods The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≥2.25 mm to 24 to ≤34 mm long in vessels ≥2.50 to ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Results One-year TLF rates with the PtCr-EES were significantly (P

Published
2014
Full Text
View/download PDF

2. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions

Author

Paul S, Teirstein, Ian T, Meredith, Robert L, Feldman, A Charles, Rabinowitz, Louis A, Cannon, Tommy C, Lee, Joseph, Dens, Christophe L, Dubois, Michael R, Mooney, Vincent J, Pompili, Shigeru, Saito, Dominic J, Allocco, Keith D, Dawkins, and Gregg W, Stone

Subjects
Chromium, Male, Sirolimus, Time Factors, Cardiovascular Agents, Drug-Eluting Stents, Coronary Artery Disease, Middle Aged, Prosthesis Design, United States, Europe, Percutaneous Coronary Intervention, Treatment Outcome, Japan, Humans, Female, Everolimus, Prospective Studies, Aged, New Zealand, Platinum
Abstract

To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies.Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation.The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≥2.25 mm to2.50 mm in diameter and ≤28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions24 to ≤34 mm long in vessels ≥2.50 to ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions.One-year TLF rates with the PtCr-EES were significantly (P0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up.The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results